Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Nanofiltration as tertiary treatment method for removing trace pharmaceutically active compounds in wastewater from wastewater treatment plants.

Garcia-Ivars J, Martella L, Massella M, Carbonell-Alcaina C, Alcaina-Miranda MI, Iborra-Clar MI.

Water Res. 2017 Nov 15;125:360-373. doi: 10.1016/j.watres.2017.08.070. Epub 2017 Sep 1.

PMID:
28881212
2.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.

J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24.

PMID:
26702926
3.

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group.

HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26.

PMID:
26611175
4.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group.

Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30.

PMID:
26520926
5.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group.

Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.

PMID:
25103176
6.
7.

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.

Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group.

J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14.

8.

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group.

Int J STD AIDS. 2012 Jul;23(7):459-63.

PMID:
22843997
9.

Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy.

Massella M, Ivanovic J, Bellagamba R, De Vita R, Fracasso L, Tozzi V, Fragola V, Rizzica M, Narciso P.

Patient Prefer Adherence. 2011;5:223-8. doi: 10.2147/PPA.S16819. Epub 2011 May 17.

10.

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group.

Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.

PMID:
20371753
11.

A factor analytic study of the Italian National Institute of Health Quality of Life - Core Evaluation Form (ISSQoL-CEF).

Lauriola M, Murri R, Massella M, Mirra M, Donnini S, Fragola V, Ivanovic J, Pavoni M, Mancini G, Bucciardini R.

Patient Prefer Adherence. 2010 Mar 24;4:33-44.

12.

Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.

Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, Massella M, Fracasso L, De Vita R, Pierro P, Del Maestro A, Mirra M, Weimer L.

AIDS Res Hum Retroviruses. 2009 Oct;25(10):979-87. doi: 10.1089/aid.2009.0029.

PMID:
19795984
13.

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy.

Bucciardini R, Massella M, Corpolongo A, Narciso P, Fragola V, Mirra M, Donnini S, Viganò O, Costarelli S, Tozzi V.

Biologics. 2008 Sep;2(3):577-81.

14.

Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy.

Bucciardini R, Fragola V, Massella M, Polizzi C, Mirra M, Goodall R, Carey D, Hudson F, Zajdenverg R, Floridia M; Initio Trial International Coordinating Committee.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1215-22.

PMID:
17961107
15.

ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era.

Bucciardini R, Murri R, Guarinieri M, Starace F, Martini M, Vatrella A, Cafaro L, Fantoni M, Grisetti R, Monforte Ad, Fragola V, Arcieri R, Del Borgo C, Tramarin A, Massella M, Lorenzetti D, Vella S.

Qual Life Res. 2006 Apr;15(3):377-90.

PMID:
16547775
16.

[Prevalence of the use of old and new drugs among new entrants in Italian prisons].

Rezza G, Scalia Tomba G, Martucci P, Massella M, Noto R, De Risio A, Brunetti B, Ardita S, Starnini G.

Ann Ist Super Sanita. 2005;41(2):239-45. Italian.

17.

Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).

Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S.

HIV Clin Trials. 2000 Sep-Oct;1(2):9-16.

PMID:
11590493
18.

Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.

Bucciardini R, Wu AW, Floridia M, Fragola V, Ricciardulli D, Tomino C, Weimer LE, Pirillo MF, Mirra M, Marzi M, Giannini G, Galluzzo CM, Andreotti M, Massella M, Vella S; Istituto Superiore di Sanità 047 Study.

AIDS. 2000 Nov 10;14(16):2567-74.

PMID:
11101069

Supplemental Content

Loading ...
Support Center